Atorvastatin in Pulmonary Arterial Hypertension (APATH) study

European Respiratory Journal

Volumn 40, Issue 1, 2012, Pages 67-74

  Zeng, Wei Jie ^a   Xiong, Chang Ming ^a   Zhao, Lan ^c   Shan, Guang Liang ^b   Liu, Zhi Hong ^a   Xue, Fang ^b   Gu, Qing ^a   Ni, Xin Hai ^a   Zhao, Zhi Hui ^a   Cheng, Xian Sheng ^a   Wilkins, Martin R ^c   He, Jian Guo ^a  

^a FUWAI HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Exercise; Haemodynamics; Hypertension; Pulmonary; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; FEMALE; HEART INDEX; HEART LEFT ATRIUM PRESSURE; HUMAN; INDIGESTION; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MYALGIA; OXYGEN SATURATION; PARESTHESIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; HEMODYNAMICS; HEPTANOIC ACIDS; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME; WALKING; YOUNG ADULT;

EID: 84863500159     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00149011     Document Type: Article

References (34)

1. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121: 2045-2066.
2. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
3. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
4. Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011; 140: 301-309.
5. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
6. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
7. Xie L, Lin P, Xie H, et al. Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats. Clin Exp Hypertens 2010; 32: 547-554.
8. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003; 285: H938-H945. (Pubitemid 37048146)
9. Guerard P, Rakotoniaina Z, Goirand F, et al. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 401-414. (Pubitemid 44401411)
10. Laudi S, Trump S, Schmitz V, et al. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 293: L630-L638. (Pubitemid 47358825)
11. Murata T, Kinoshita K, Hori M, et al. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2005; 25: 2335-2342. (Pubitemid 41552651)
12. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002; 166: 1403-1408. (Pubitemid 35292709)
13. Rakotoniaina Z, Guerard P, Lirussi F, et al. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol 2006; 374: 195-206. (Pubitemid 44819252)
14. Satoh K, Fukumoto Y, Nakano M, et al. Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009; 81: 226-234.
15. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108: 1640-1645. (Pubitemid 37187793)
16. Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1105-L1110. (Pubitemid 47084854)
17. Zhao L, Sebkhi A, Ali O, et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009; 34: 948-957.
18. Gao YF, Zhu XD, Shi DM, et al. The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats. Int J Mol Med 2010; 26: 541-547.
19. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005; 127: 1446-1452. (Pubitemid 46224314)
20. Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 2010; 181: 1106-1113.
21. Kawut SM, Bagiella E, Lederer DJ, et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011; 123: 2985-2993.
22. Barreto AC, Maeda NY, Soares RP, et al. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. Braz J Med Biol Res 2008; 41: 657-663.
23. ATS statement. guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
24. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 14S-34S. (Pubitemid 38932340)
25. Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009; 33: 1354-1360.
26. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: Suppl. 1, 78S-92S. (Pubitemid 38932344)
27. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435. (Pubitemid 40471450)
28. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692. (Pubitemid 32588024)
29. Galie N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006; 3: 571-576. (Pubitemid 44411622)
30. Beghetti M, Tissot C. Pulmonary arterial hypertension in congenital heart diseases. Semin Respir Crit Care Med 2009; 30: 421-428.
31. Kimura H, Okada O, Tanabe N, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 319-324. (Pubitemid 34001302)
32. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100. (Pubitemid 351902178)
33. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
34. Quarck R, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211-1218.